REPL vs. BLUE, ALVR, ATRA, VIR, BEAM, PTGX, AMRX, DCPH, BHC, and CPRX
Should you be buying Replimune Group stock or one of its competitors? The main competitors of Replimune Group include bluebird bio (BLUE), AlloVir (ALVR), Atara Biotherapeutics (ATRA), Vir Biotechnology (VIR), Beam Therapeutics (BEAM), Protagonist Therapeutics (PTGX), Amneal Pharmaceuticals (AMRX), Deciphera Pharmaceuticals (DCPH), Bausch Health Companies (BHC), and Catalyst Pharmaceuticals (CPRX). These companies are all part of the "medical" sector.
Replimune Group (NASDAQ:REPL) and bluebird bio (NASDAQ:BLUE) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their community ranking, risk, profitability, dividends, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.
bluebird bio's return on equity of 0.00% beat Replimune Group's return on equity.
92.5% of Replimune Group shares are owned by institutional investors. Comparatively, 87.4% of bluebird bio shares are owned by institutional investors. 20.6% of Replimune Group shares are owned by company insiders. Comparatively, 2.1% of bluebird bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
In the previous week, Replimune Group and Replimune Group both had 3 articles in the media. Replimune Group's average media sentiment score of 1.24 beat bluebird bio's score of 0.40 indicating that Replimune Group is being referred to more favorably in the media.
Replimune Group has a beta of 1.25, indicating that its stock price is 25% more volatile than the S&P 500. Comparatively, bluebird bio has a beta of 0.81, indicating that its stock price is 19% less volatile than the S&P 500.
bluebird bio received 880 more outperform votes than Replimune Group when rated by MarketBeat users. Likewise, 71.78% of users gave bluebird bio an outperform vote while only 62.00% of users gave Replimune Group an outperform vote.
Replimune Group presently has a consensus target price of $16.67, indicating a potential upside of 61.03%. bluebird bio has a consensus target price of $5.46, indicating a potential upside of 347.75%. Given bluebird bio's higher probable upside, analysts clearly believe bluebird bio is more favorable than Replimune Group.
Replimune Group has higher earnings, but lower revenue than bluebird bio. Replimune Group is trading at a lower price-to-earnings ratio than bluebird bio, indicating that it is currently the more affordable of the two stocks.
Summary
bluebird bio beats Replimune Group on 8 of the 14 factors compared between the two stocks.
Get Replimune Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for REPL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding REPL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Replimune Group Competitors List
Related Companies and Tools
